Ardelyx, Inc. (NASDAQ:ARDX) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET
Company Participants
Kimia Keshtbod - Investor Relations
Justin Renz - Chief Financial Officer
Susan Rodriguez - Chief Commercial Officer
Laura Williams - Chief Medical Officer
David Rosenbaum - Chief Development Officer
Rob Blanks - Chief Regulatory Affairs and Quality Assurance Officer
Conference Call Participants
Yigal Nochomovitz - Citigroup
Laura Chico - Wedbush Securities
Joseph Thome - Cowen and Company
Matt Kaplan - Ladenburg Thalmann
Chris Howerton - Jefferies
Operator
Welcome to the Ardelyx Third Quarter 2022 Earnings Conference Call. My name is Sean. I will be your operator for today’s call. [Operator Instructions] As a reminder, this conference call is being recorded. I will now turn the call over to Kimia Keshtbod of Ardelyx. You may begin.
Kimia Keshtbod
Thank you and good afternoon, everyone and welcome to our third quarter financial results call. During this call, we will refer to the press release issued earlier today, which is available in the Investors section of the company’s website at ardelyx.com.
On the call with me today are Justin Renz, Chief Financial Officer; and Susan Rodriguez, Chief Commercial Officer with prepared remarks. Dr. Laura Williams, Chief Medical Officer; Dr. David Rosenbaum, Chief Development Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer will join us for the question-and-answer period. Our CEO, Mike Raab, won’t be on this call as he is doing well, recovering from a recent surgery and will be back soon.
During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our quarterly report on Form 10-Q filed today, which can also be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
With that, let me pass the call over to Justin for opening remarks.
Justin Renz
Thank you, Kimia, and good afternoon, everyone. It is with great pleasure that I provide you an update on our progress since our last call. We are in a notable position to be a stand-alone drug innovator in the midst of commercializing our first-in-class drug discovered and developed by Ardelyx and generating revenue while advancing our pipeline. We are now 6 months into launch, and we’re pleased to report that IBSRELA is resonating with prescribers and patients as an important new treatment option for IBS-C. We are clearly gaining traction and building momentum in this marketplace. These early days have given us confidence that both patients and prescribers are embracing IBSRELA, and they are having a positive experience with the drug.